Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $2.0 million.

  • Beam Therapeutics' Change in Accured Expenses rose 120.07% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.7 million, marking a year-over-year decrease of 163.65%. This contributed to the annual value of -$57.7 million for FY2024, which is 185.25% down from last year.
  • Per Beam Therapeutics' latest filing, its Change in Accured Expenses stood at $2.0 million for Q3 2025, which was down 79.97% from $9.9 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Change in Accured Expenses ranged from a high of $70.4 million in Q4 2023 and a low of -$24.3 million during Q1 2024.
  • For the 3-year period, Beam Therapeutics' Change in Accured Expenses averaged around $305,909, with its median value being -$4.1 million (2024).
  • As far as peak fluctuations go, Beam Therapeutics' Change in Accured Expenses surged by 1,359.38% in 2021, and later plummeted by 7,225.56% in 2024.
  • Quarterly analysis of 5 years shows Beam Therapeutics' Change in Accured Expenses stood at $41.1 million in 2021, then slumped by 79.46% to $8.4 million in 2022, then skyrocketed by 733.84% to $70.4 million in 2023, then tumbled by 105.79% to -$4.1 million in 2024, then skyrocketed by 120.07% to $2.0 million in 2025.
  • Its Change in Accured Expenses stands at $2.0 million for Q3 2025, versus $9.9 million for Q2 2025 and -$18.5 million for Q1 2025.